VitriVax awarded $9.9M grant to enable scaling up of clinical manufacturing
Business Wire—VitriVax Inc., a ºÚÁÏÉçÇøÍø vaccine formulation technology spinout, today announced it has been awarded a two-year, $9.9 million grant from the Gates Foundation. The funding will support the scale-up of VitriVax’s Atomic Layering Thermostable Antigen and Adjuvant (ALTA®) technology, enabling Phase 1-ready GMP manufacturing and advancing the platform to prepare for Phase 1 clinical trials.
The University of Colorado Connection
VitriVax is a biotechnology company working to eliminate barriers to global vaccination, and has developed a novel stabilization and delivery platform for vaccines and therapeutics based on research in the laboratories of (ºÚÁÏÉçÇøÍø Molecular, Cellular & Developmental Biology) and Ìýat ºÚÁÏÉçÇøÍø (ºÚÁÏÉçÇøÍø Chemical and Biological Engineering).
The Newsroom
For marketing and communication inquiries or news tips, contact Daniel Leonard,Ìýsenior marketing and communications specialist for Venture Partners at ºÚÁÏÉçÇøÍø.
For media inquiries, please visit .